Citius Pharmaceuticals, Inc. financial data

Symbol
CTXR on Nasdaq
Industry
Pharmaceutical Preparations
Location
11 Commerce Drive, 1 St Floor, Cranford, NJ
State of incorporation
NV
Fiscal year end
September 30
Former names
Trail One, Inc. (to 9/18/2014), TrailOne, Inc. (to 1/21/2011)
Latest financial report
10-Q - Q4 2024 - Feb 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 92.3 % -84.4%
Debt-to-equity 38.6 % +188%
Return On Equity -44.7 % -44%
Return On Assets -39.4 % -41.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 7.73M shares -95.1%
Common Stock, Shares, Outstanding 7.73M shares -95.1%
Entity Public Float 157M USD -34.6%
Common Stock, Value, Issued 7.73K USD -95.1%
Weighted Average Number of Shares Outstanding, Basic 7.49M shares +17.8%
Weighted Average Number of Shares Outstanding, Diluted 7.49M shares +17.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 11.4M USD -18.5%
General and Administrative Expense 20M USD +22.2%
Operating Income (Loss) -42.7M USD -9.97%
Nonoperating Income (Expense) 2.91M USD +139%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -39.8M USD -5.78%
Net Income (Loss) Attributable to Parent -38.3M USD -25.2%
Earnings Per Share, Basic -1.3 USD/shares +10.3%
Earnings Per Share, Diluted -1.3 USD/shares +10.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.1M USD -94.6%
Inventory, Net 14.4M USD
Assets, Current 18.3M USD -35%
Property, Plant and Equipment, Net 275 USD -89.6%
Operating Lease, Right-of-Use Asset 191K USD -52.6%
Goodwill 9.35M USD 0%
Other Assets, Noncurrent 102M USD
Assets 121M USD +23.9%
Accounts Payable, Current 7.36M USD +178%
Employee-related Liabilities, Current 2.6M USD +6.76%
Accrued Liabilities, Current 6.24M USD +2154%
Liabilities, Current 44.8M USD +703%
Deferred Income Tax Liabilities, Net 6.98M USD +11.1%
Operating Lease, Liability, Noncurrent 21.3K USD -91.9%
Liabilities 51.8M USD +329%
Retained Earnings (Accumulated Deficit) -211M USD -23.1%
Stockholders' Equity Attributable to Parent 65.4M USD -22.8%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 68.9M USD -19.2%
Liabilities and Equity 121M USD +23.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.73M USD +23%
Net Cash Provided by (Used in) Financing Activities 2.57M USD
Common Stock, Shares Authorized 16M shares -96%
Common Stock, Shares, Issued 7.73M shares -95.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.1M USD -94.6%
Deferred Tax Assets, Valuation Allowance 53.8M USD +19.8%
Operating Lease, Liability 205K USD -52.3%
Depreciation 578 USD -20.8%
Lessee, Operating Lease, Liability, to be Paid 212K USD -54.1%
Operating Lease, Liability, Current 205K USD -8.68%
Lessee, Operating Lease, Liability, to be Paid, Year Two 21.5K USD -91.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 21.5K USD -91.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Deferred Income Tax Expense (Benefit) 264K USD +83.5%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 7.61K USD -77.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 21.5K USD
Deferred Tax Assets, Operating Loss Carryforwards 39.9M USD +14%
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 277M USD +8.01%
Share-based Payment Arrangement, Expense 11.3M USD -17.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%